Case Studies in Multiple Myeloma Care for Challenging Times – Part 2: Relapsed Multiple Myeloma
Release Date: April 09, 2021
Expiration Date: April 09, 2022
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity on multiple myeloma care for challenging times will include common treatment regimens in early relapsed MM; clinical trials including phases, myths, and how to find them; and nursing management, including symptom management. Through the cases of Joshua - a standard-risk patient experiencing a slow biochemical progression, and Kristen - a high-risk patient experiencing a symptomatic relapse, our faculty will focus on symptom management, infection control, and nursing implications. Please remember to complete part 1 and 3 to receive a total of 1.5 CNE credits (3 sessions at 0.5 CNE). Free downloadable tools and resources are provided after completing the post-test and activity evaluation survey.
This activity is designed for nurses and other medical personnel involved in care of patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify common treatment regimens in newly diagnosed and relapsed multiple myeloma
- Discuss effective symptom management and education of patients with multiple myeloma receiving treatment regimens in the newly diagnosed and relapsed setting
- Discuss healthcare disparities faced by patients with multiple myeloma who are part of diverse groups, such as African Americans, and identify steps to address barriers to care for underserved populations
- Describe strategies to support optimizing patient myeloma care through topics such as shared decision making and telehealth techniques
Relapsed Multiple Myeloma
- Common treatment regimens in early relapsed Multiple Myeloma
- Clinical trials including phases, myths, and how to find them
- Nursing management, including symptom management
- Two case studies:
- Joshua - a standard-risk patient experiencing a slow biochemical progression
- Kristen - a high-risk patient experiencing a symptomatic relapse
Instructions for Participation and Credit
This activity is eligible for credit through April 09, 2022. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You will be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 100%. You will be able to review the correct answers along with the rationale before completing the program. Please note you must achieve a passing score within 3 attempts or you will be unable to complete the activity and earn CNE credit.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.
- Your online certificate will be saved on ManagingMyeloma.com in your CE Records, which you can access at any time using your login.
Adult Nurse Practitioner
Multiple Myeloma Program
Cleveland Clinic Taussig Cancer Institute
Dr. Beth Faiman received a Bachelor of Science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a Master of Science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD in Clinical Research and Nursing from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is currently employed as an Adult Nurse Practitioner in the department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio. She is an appointed member in the Cancer Prevention Control and Population Research Program, Case Comprehensive Cancer Center as well as adjunct faculty at Ursuline College, Case Western Reserve University, and Kent State University. Dr. Faiman is the recipient of a many awards including the 2012 Excellence in Medical Oncology, the 2013 Commendation for Patient and Nursing Education Award sponsored by The Oncology Nursing Society, and the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University. She was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016. Additionally, Dr. Faiman was recognized by the American Academy of Nursing for her contributions to healthcare through selection to the American Academy of Nursing in 2019 and was appointed by the American Board of Internal Medicine (ABIM) to ABIM Hematology Specialty Board in July 2019. The ABIM is responsible for governing the licensure of current and future board-certified hem/onc physicians.
Dr. Faiman is an active author, presenter, and educator on the topics of multiple myeloma, amyloidosis, chronic leukemia, plasma cell dyscrasias, and general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is currently Editor-in-Chief of the Journal of the Advanced Practitioner in Oncology (JADPRO), former founding Editor-In-Chief of the Oncology Nurse APN-PA, and former founding editorial board member of ASH Clinical News. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman has served as a prolific speaker, publisher, and committee leader conducting original research for over fourteen years as a distinguished member of the International Myeloma Foundation Nurse Leadership Board.
Donna Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, NY
Donna Catamero received a Bachelor of Science in nursing from Simmons College in 2002 and her Master of Science in nursing from NYU in 2010. For 20 years, Ms. Catamero has been involved in clinical research. She worked as a Nurse Practitioner in the Multiple Myeloma Program at New York University Langone Medical Center in New York City and later at Mount Sinai, also in New York City, until 2018. Then Ms. Catamero spent two years in industry working as Scientific Director of Medical Affairs in multiple myeloma where she developed expertise in both BCMA research and education development for healthcare providers. She is now back at Mount Sinai where she serves as Associate Director of Myeloma Translational Research. In this position, she oversees clinical research projects and develops standards of care for professional practice.
Ms. Catamero is an active author, presenter, and educator including co-authoring “On the Horizon,” the concluding chapter in Multiple Myeloma: A Textbook for Nurses (3rd ed.) addressing the rapidly changing landscape of myeloma. Having worked on the frontlines during the initial COVID surge in New York City, among her many publications was a timely article on “Considerations of COVID-19–Specific Myeloma Guidelines in New York City.” Ms. Catamero has recently presented for the JADPRO Roundtable and for Myeloma Australia.
Ms. Catamero is deeply devoted to her patients, including personal efforts to raise awareness and funds for myeloma research. Ms. Catamero first joined the IMF Nurse Leadership Board (NLB) in 2014, and the NLB considers themselves fortunate to have her back. Over the past year, she has served as a chairperson for roundtables and advisory boards, presented at an IMF Patient & Family Seminar, and as faculty for the NLB Symposium at ONS for the 2nd time. Ms. Catamero embraces the opportunity to assist the NLB in its mission to work with both nurses and patients to improve the lives of those with multiple myeloma.
|Nursing Continuing Education
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
0.5 contact hours may be earned for successful completion of this activity. A total of 1.5 contact hours may be earned by completing all 3 activities in this course.
Accreditor Disclosure of Conflicts of Interest PolicyThe Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Disclosure of Conflicts of InterestIt is the policy of the Annenberg Center for Health Sciences at Eisenhower to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, the Annenberg Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are mitigated by the Annenberg Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
The faculty reported the following financial relationships and/or other relationships they have with ineligible organizations related to the content of this CNE/CE activity:
Name of Faculty
Reported Financial Relationship
|Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN||
Consulting with BMS/Celgene, Karyopharm, GSK, Sanofi
|Donna D. Catamero, ANP-BC, OCN, CCRC||
Consulting with BMS/Celgene (and former employee); GSK & Oncopeptides speaker
All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant relationships to disclose.
The content and program managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
Content or Program Manager
Reported Financial Relationship
Joyce Divine, PhD, MBA
None to disclose
Michelle Faber, MS
None to disclose
Diane Moran, RN, MA, EdM
None to disclose
Maya Ormsby, MS, MBA, MIM
None to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
A presentation timeslot has been assigned to provide a symposium supported by the International Myeloma Foundation during the Oncology Nursing Society’s (ONS) Congress Virtual Event. The Oncology Nursing Society's assignment of a presentation timeslot does not imply product endorsement.
Provided by the International Myeloma Foundation
Accredited by Annenberg Center for Health Sciences at Eisenhower
This accredited education activity is supported by educational grants from AbbVie Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Karyopharm Therapeutics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Oncopeptides, Inc.; and Sanofi Genzyme.
©2021 International Myeloma Foundation, 12650 Riverside Drive, Suite 206, North Hollywood, CA 91607, USA, Tel: 1-818-487-7455
No portion of this material may be copied or duplicated without the expressed permission of the International Myeloma Foundation.